Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction
Cardiovascular comorbidities are pervasive in chronic obstructive pulmonary disease (COPD) and often result in serious adverse cardiovascular events. Tongxinluo (TXL) has been clinically verified to treat atherosclerosis (AS), improve lung function and alleviate dyspnoea. The present study aimed to...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2a665de1bced4d65ae3a51db368c2d5a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2a665de1bced4d65ae3a51db368c2d5a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2a665de1bced4d65ae3a51db368c2d5a2021-11-04T04:26:11ZTongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction0753-332210.1016/j.biopha.2021.112367https://doaj.org/article/2a665de1bced4d65ae3a51db368c2d5a2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221011513https://doaj.org/toc/0753-3322Cardiovascular comorbidities are pervasive in chronic obstructive pulmonary disease (COPD) and often result in serious adverse cardiovascular events. Tongxinluo (TXL) has been clinically verified to treat atherosclerosis (AS), improve lung function and alleviate dyspnoea. The present study aimed to explore the effect of lung microvascular barrier dysfunction on AS in COPD and the potential pulmonary protective mechanisms of TXL in COPD complicated with AS. COPD complicated with AS was induced in mice by cigarette smoke (CS) exposure and high-fat diet (HFD) feeding. The mice were treated with atorvastatin (ATO), TXL or combination therapy (ATO+TXL) for 20 weeks. Pulmonary function, lung pathology, serum lipid levels, atherosclerotic plaque area and indicators of barrier function, oxidative stress and ferroptosis in lung tissue were evaluated. In vitro, human pulmonary microvascular endothelial cells (HPMECs) were pretreated with TXL for 4 h and then incubated with cigarette smoke extract (CSE) and homocysteine (Hcy) for 36 h to induce barrier dysfunction. Then the indicators of barrier function, oxidative stress and ferroptosis were measured. The results demonstrate that CS aggravated dyslipidaemia, atherosclerotic plaque formation, pulmonary function decline, pathological injury, barrier dysfunction, oxidative stress and ferroptosis in the HFD-fed mice. However, these abnormalities were partially reversed by ATO and TXL. Similar results were observed in vitro. In conclusion, pulmonary microvascular barrier dysfunction plays an important role by which COPD affects the progression of AS, and ferroptosis may be involved. Moreover, TXL delays the progression of AS and reduces cardiovascular events by protecting the pulmonary microvascular barrier and inhibiting ferroptosis.Yafen WangXiangnan KuangYujie YinNingxin HanLiping ChangHongtao WangYunlong HouHuixin LiZhen LiYi LiuYuanjie HaoYaru WeiXiaoqi WangZhenhua JiaElsevierarticleTongxinluoChronic obstructive pulmonary diseaseAtherosclerosisPulmonary microvascular barrierOxidative stressFerroptosisTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 145, Iss , Pp 112367- (2022) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Tongxinluo Chronic obstructive pulmonary disease Atherosclerosis Pulmonary microvascular barrier Oxidative stress Ferroptosis Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
Tongxinluo Chronic obstructive pulmonary disease Atherosclerosis Pulmonary microvascular barrier Oxidative stress Ferroptosis Therapeutics. Pharmacology RM1-950 Yafen Wang Xiangnan Kuang Yujie Yin Ningxin Han Liping Chang Hongtao Wang Yunlong Hou Huixin Li Zhen Li Yi Liu Yuanjie Hao Yaru Wei Xiaoqi Wang Zhenhua Jia Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction |
| description |
Cardiovascular comorbidities are pervasive in chronic obstructive pulmonary disease (COPD) and often result in serious adverse cardiovascular events. Tongxinluo (TXL) has been clinically verified to treat atherosclerosis (AS), improve lung function and alleviate dyspnoea. The present study aimed to explore the effect of lung microvascular barrier dysfunction on AS in COPD and the potential pulmonary protective mechanisms of TXL in COPD complicated with AS. COPD complicated with AS was induced in mice by cigarette smoke (CS) exposure and high-fat diet (HFD) feeding. The mice were treated with atorvastatin (ATO), TXL or combination therapy (ATO+TXL) for 20 weeks. Pulmonary function, lung pathology, serum lipid levels, atherosclerotic plaque area and indicators of barrier function, oxidative stress and ferroptosis in lung tissue were evaluated. In vitro, human pulmonary microvascular endothelial cells (HPMECs) were pretreated with TXL for 4 h and then incubated with cigarette smoke extract (CSE) and homocysteine (Hcy) for 36 h to induce barrier dysfunction. Then the indicators of barrier function, oxidative stress and ferroptosis were measured. The results demonstrate that CS aggravated dyslipidaemia, atherosclerotic plaque formation, pulmonary function decline, pathological injury, barrier dysfunction, oxidative stress and ferroptosis in the HFD-fed mice. However, these abnormalities were partially reversed by ATO and TXL. Similar results were observed in vitro. In conclusion, pulmonary microvascular barrier dysfunction plays an important role by which COPD affects the progression of AS, and ferroptosis may be involved. Moreover, TXL delays the progression of AS and reduces cardiovascular events by protecting the pulmonary microvascular barrier and inhibiting ferroptosis. |
| format |
article |
| author |
Yafen Wang Xiangnan Kuang Yujie Yin Ningxin Han Liping Chang Hongtao Wang Yunlong Hou Huixin Li Zhen Li Yi Liu Yuanjie Hao Yaru Wei Xiaoqi Wang Zhenhua Jia |
| author_facet |
Yafen Wang Xiangnan Kuang Yujie Yin Ningxin Han Liping Chang Hongtao Wang Yunlong Hou Huixin Li Zhen Li Yi Liu Yuanjie Hao Yaru Wei Xiaoqi Wang Zhenhua Jia |
| author_sort |
Yafen Wang |
| title |
Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction |
| title_short |
Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction |
| title_full |
Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction |
| title_fullStr |
Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction |
| title_full_unstemmed |
Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction |
| title_sort |
tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction |
| publisher |
Elsevier |
| publishDate |
2022 |
| url |
https://doaj.org/article/2a665de1bced4d65ae3a51db368c2d5a |
| work_keys_str_mv |
AT yafenwang tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT xiangnankuang tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT yujieyin tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT ningxinhan tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT lipingchang tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT hongtaowang tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT yunlonghou tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT huixinli tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT zhenli tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT yiliu tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT yuanjiehao tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT yaruwei tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT xiaoqiwang tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction AT zhenhuajia tongxinluopreventschronicobstructivepulmonarydiseasecomplicatedwithatherosclerosisbyinhibitingferroptosisandprotectingagainstpulmonarymicrovascularbarrierdysfunction |
| _version_ |
1718445263392079872 |